• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230).
  

PubMed=2441858
Kelland L.R., Burgess L., Steel G.G.
Characterization of four new cell lines derived from human squamous carcinomas of the uterine cervix.
Cancer Res. 47:4947-4952(1987)

PubMed=2475347; DOI=10.1016/0277-5379(89)90417-3
Kelland L.R., Tonkin K.S.
In vitro chemosensitivity of four new carcinoma of the cervix cell lines: relationship to radiosensitivity.
Eur. J. Cancer Clin. Oncol. 25:1211-1218(1989)

PubMed=8347478; DOI=10.1038/bjc.1993.322; PMCID=PMC1968570
Mellish K.J., Kelland L.R., Harrap K.R.
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
Br. J. Cancer 68:240-250(1993)

PubMed=7751322; DOI=10.1007/BF01366967
Rantanen V., Grenman S.E., Kulmala J., Grenman R.
The intrinsic radiosensitivity and sublethal damage repair capacity of five cervical carcinoma cell lines tested with the 96-well-plate assay.
J. Cancer Res. Clin. Oncol. 121:230-234(1995)

PubMed=9887230; DOI=10.1006/gyno.1998.5194
Rantanen V., Grenman S.E., Kurvinen K., Hietanen S.H., Raitanen M., Syrjanen S.M.
p53 mutations and presence of HPV DNA do not correlate with radiosensitivity of gynecological cancer cell lines.
Gynecol. Oncol. 71:352-358(1998)

PubMed=35692560; DOI=10.1080/23723556.2022.2078628; PMCID=PMC9176225
de Lourdes Zuniga-Martinez M., Lopez-Mendoza C.M., Tenorio-Salazar J., Garcia-Carranca A.M., Cerbon-Cervantes M.A., Alcantara-Quintana L.E.
Establishment, authenticity, and characterization of cervical cancer cell lines.
Mol. Cell. Oncol. 9:2078628.1-2078628.10(2022)